Inhibition of CCL2 could break this loop and reverse the enhanced BC cell tumor proliferation and migration caused by EZH2 inhibitors, which suggested that combinational inhibition of CCL2 with EZH2 inhibitors may be beneficial to the treatment of breast cancer. Here, CCL2 is linked to breast carcinoma.